Tempus AI (TEM) shares closed at $68.85 on Tuesday, September 15, up 10.7% on the day, following management's presentation at a Morgan Stanley conference. The stock was hovering near $68.63 in premarket trading on Wednesday morning, according to Nasdaq data carried by Yahoo Finance.
The rally was fueled by a key figure: approximately $200 million in total contract value (TCV) that customers signed for new data and applications licenses during the second quarter. This represents bookings, not recognized revenue, but investors are assigning value to these future contracts today.
Chief Executive Eric Lefkofsky reported that data licensing grew about 36% in the latest quarter, with the company recording more than $100 million in new TCV in each of the past three quarters. His remarks were detailed in a Form 425 transcript filed with the SEC on September 15.
Lefkofsky attributed the acceleration to biopharma companies increasingly adopting artificial intelligence, which requires curated clinical and molecular data to train and validate models. He also floated the prospect of well-funded AI developers becoming major buyers in the future, though that remains an opportunity case rather than contracted revenue.
The more concrete proof point lies in the numbers: Tempus reported that data licensing and modeling revenue rose 36% in the June quarter and disclosed about $200 million in new licenses signed during that period. The company's competitive advantage, according to management, stems from the extensive preparation required before data can be sold—connecting to thousands of hospitals, negotiating rights, de-identifying records, and structuring unstandardized information.
Tempus now holds roughly 500 petabytes of data, but scale alone does not guarantee pricing power. The consecutive bookings figures offer a measurable test of whether customers value that preparation.
However, Tempus is not a pure data-licensing play. Second-quarter revenue reached $382.5 million, up 22% year-over-year, while oncology test volume increased 31%. Diagnostics remains its largest operation and provides the fresh clinical data that feeds its data products. This integration is valuable but leaves the company exposed to reimbursement rates, laboratory costs, and test mix.
The proposed acquisition of Personalis adds another layer of complexity. Tempus had been receiving about $400 per Personalis test it distributed, even when Personalis was not reimbursed. Lefkofsky suggested that improving coverage for lung, breast, and immunotherapy-response testing could push average selling prices above that distribution fee, changing the economics in favor of ownership. Yet the parties' own 2030 forecasts diverged sharply: the conference transcript cites $758 million for Personalis against Tempus's $333 million estimate, with Lefkofsky attributing most of the gap to pricing assumptions and choosing the more conservative path.
The bull case rests on two observable pillars: signed data-license value converting into revenue, and diagnostic pricing improving without sacrificing volume. A new class of hyperscaler customers would be upside, but treating that as the base case would run ahead of disclosed contracts.
The counterweight is that Tempus is still absorbing acquisition and integration risk while profitability remains uneven. It earned $5.6 million in the second quarter, but its June 30 filing shows a $120.3 million net loss for the first six months of 2026. The next useful checks are prosaic: recognized data revenue versus bookings, oncology volume, reimbursement-driven average selling prices, and progress integrating Personalis. Those figures, rather than speculative AI spending, will determine whether Tuesday's re-rating holds.
